Browse products
Generic and innovative drugs market in Poland 2012Development forecasts for 2012-2014 |
Polish version also available »
Our clients say...
“Sanofi-Aventis group regularly order PMR's reports and newsletters concerning the Polish pharmaceutical market. We use PMR's services because of the wealth of experience of its analysts in undertaking market analysis and a high level of quality and involvement in the field of market research. ”
General Manager, Sanofi-Synthelabo
“PMR provides a good service and is always open to discussion. All reports are well structured & are always on time.”
Member of the Managment Board, SCA Hygiene Products
“We consider PMR a competent and professional company. PMR analysts understand our needs clearly and their services have fully met our expectations. I strongly recommend the company as a reliable partner in providing economic information and market analysis.”
General Manager, Sanofi-Synthelabo
“It's a great pleasure to cooperate with PMR because of its analysts' wealth of experience in understanding the local market. We consider PMR a competent and professional company which helps us conduct our business. I would also like to state that PMR's team is always ready to respond to emerging customer needs. We can recommend it as a reliable partner.”
Business Analyst, Hilti Distribution, Russia
“As a London-based company, with operations abroad, we looked for the best-in-class Market Intelligence supplier. PMR brought us quality reports that improved our CEE market knowledge and understanding.”
Development Manager, GVA Grimley
“We use PMR's services due to their analysts' extensive experience in market analysis, their high quality and level of engagement in the market research carried out for us. We consider PMR a competent and professional company and recommend them as a reliable partner in the area of economic information and market analysis.”
Senior Trade and Investment Adviser, British Embassy in Warsaw
“PMR's analysts understand our needs well and the standard of their service has always fully met our expectations. We are looking forward to cooperating with PMR in the future as well. ”
Senior Trade and Investment Adviser, British Embassy in Warsaw
“PMR reports are a serious contribution to the market overview picture, focusing our attention on key events in the industry as well as highlighting both general and specific market indicators. Together, these components are the base for our future forecasts of construction market development and help us to plan our sales.
”
Market Analyst, Alpha Cement
The report is a comprehensive analysis of the pharmaceutical market in Poland following the introduction of the reimbursement act. It presents the details of the key provisions of the act, as well as the possible actions that companies can take in order to minimise its negative impact.
The publication also contains development forecasts for 2012-2014, for both the entire market and the market of prescription medicines – broken down into innovative and generic segments.
In addition to insightful analysis, the report presents the profiles of top generic and innovative producers in Poland, and an assessment of the impact on each company of the reimbursement act and the changes to the refunded drug lists.
Key topics covered:
Did you know...
“In recent years there has been an increasing number of projects in Poland focusing on innovative research.”
“The reimbursement act has introduced a ban on advertising pharmacies in Poland.”
“Changes in legislation will boost parallel export of medicines from Poland.”
“In 2007-2011 the Agency for Health Technology Assessment issued a total of 651 recommendations.”
“Generic products have dominated the Polish pharmaceutical market.”
“Currently, wholesale and retail profit margins on medicines in Poland are fixed.”
- The share of generic and innovative drugs in the pharmaceutical market and the Rx market - in terms of value and volume
- Development forecasts for generic medicines in Poland in 2012-2014
- Development forecasts for innovative medicines in Poland in 2012-2014
- Average prices of innovative and generic drugs in Poland
- Prices of innovative and generic drugs in Poland in comparison to other countries
- Generic substitution procedures
- The outlays of the National Health Fund for the reimbursement of chemotherapy and on therapy programmes
- A comparison of the operating principles of therapy programmes and medication programmes
- The reimbursement decision-making process in Poland
- Drug payment structure in Poland from the point of view of the patient and the state
- Medicines generating the highest reimbursement costs for the National Health Fund
- New active substances added to the lists of drugs refunded in Poland
- An analysis of the recent changes on the lists of refunded drugs
- The expected changes concerning drug reimbursement
- A summary of the key changes introduced by the reimbursement act
- Fixed reimbursement outlays of the National Health Fund and the payback mechanism
- Limit groups
- An assessment of the effects of the reimbursement act on market players
- Ways to minimise the negative impact ofthe reimbursement act on producers in Poland
- Top manufacturers of innovative and generic medicines in Poland
- Changes in the prices of selected products of the top generic and innovative drug manufacturers on the subsequent lists of refunded drugs
- An assessment of the impact of the reimbursement act on the top manufacturers of generic and innovative drugs.
Questions answered by the report:
- Which segment is going to grow faster in the coming years: generic or original medicines?
- Has the share of original drugs in the Polish pharmaceutical market expanded or contracted in the last few years?
- Are the prices of generic drugs lower in Poland than in other countries?
- What are the main implications of the reimbursement act for pharmaceutical companies?
- Which companies had to lower their prices the most after the negotiations with the Minister of Health?
- How long is the reimbursement decision-making process in Poland?
- What is the role of the Transparency Commission and the Head of the Agency for Health Technology Assessment (AOTM) when making a reimbursement decision?
- What are the risk-sharing instruments?
- How are reimbursement limits for limit groups determined?
- What medication/substances may become refunded in Poland in the near future?
Unique features include
- Development forecasts for generic and innovative drugs in 2012-2014 in light of the new reimbursement act
- Ways to minimise the negative impact of the act on producers.
Companies mentioned in this report:
Adamed, AstraZeneca, Bayer, Bioton, Boehringer Ingelheim, Bristol-Myers Squibb, Egis, Eli Lilly, Gedeon Richter, GlaxoSmithKline, Janssen-Cilag, Jelfa, Krka, Merck & Co., Merck Sharp & Dohme (MSD), Novartis, Novo Nordisk, Nycomed, Pfizer, Pliva, Roche, Sandoz, Sanofi, Servier, Teva, Zentiva.
Business and Industry events
- Introduction of the new reimbursement act (1 January 2012), which: introduces risk-sharing instruments, introduces fixed prices and price margins for refunded drugs, and sets limit groups under a common funding limit
- Price negotiations between pharmaceutical companies and the Ministry of Health at the end of 2011 resulted in substantially reduced prices of refunded drugs
- Changes in the lists of refunded drugs from November 2011, December 2011 and February 2012.
This report is especially useful when...
- Beginning operations in the generic drug segment in Poland
- Beginning operations in the innovative drug segment in Poland
- Developing a product portfolio of generic and/or innovative medicines
- Analyzing Polish regulatory policy with regard to generic and/or innovative medicines
- Monitoring latest changes to the reimbursement lists in Poland
- Estimating the growth potential of generic and/or innovative medicines in Poland
- Preparing forecasts about the generic drug segment in Poland
- Preparing forecasts about the innovative drug segment in Poland.
We recommend this report for:
- Manufacturers and distributors of generic and/or innovative medicines
- Companies planning to enter the Polish pharmaceutical market
- Companies with a business focus on generic and/or innovative medicines
- Consulting, research and analysis firms
- Government institutions, embassies, universities and research institutes
- Chambers of commerce, trade and industry organisations
- Financial institutions (banks, brokerage houses, investment funds, private equity funds).
Extract from this report
- According to our forecasts, in the coming years the generic medicines market in Poland will develop faster than the innovative drugs market, mainly due to the reimbursement act and changes on the lists of reimbursed medicines. This will bring cuts to the outlays of the National Health Fund on reimbursement, itself impacting heavily on the segment of innovative medicines.
- Limit groups covered by common funding limit. The basis of the limit is the highest value among the lowest wholesale prices per daily dose of a medicine that completes 15% of the monthly volume sales achieved in a given limit group.
Market commentary by expert
Expert commentary:The reimbursement act that entered into force in January 2012 will revolutionise the Polish pharmaceutical market and greatly impact the production of both generic and innovative drugs.
The key changes are concerned with fixing the reimbursement expense ceiling at 17% of the whole budget of the National Health Fund, introducing risk-sharing instruments, introducing fixed prices and price margins for refunded drugs, and determining limit groups under a common funding limit.
Agnieszka Skonieczna, Senior pharmaceutical market Analyst
Request sample pages/interactive screenshare
Generic and innovative drugs market in Poland 2012
Development forecasts for 2012-2014
Choose your version of this product:
| Language / Licence | Single | 5 Users | Corporate | Global |
| English or Polish | 1900€ | 2850€ | 3800€ | 4750€ |
| English and Polish | 2660€ | 3990€ | 5320€ | 6650€ |
Compare licences
- - for the product preservation: saving the product in the memory of one computer belonging to the client;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for the individual use of one person only, who is indicated by the client during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
- - for the product preservation: saving the product in the memory of 2 to 5 computers belonging to the organisation indicated by the client while purchasing process; these computers must be located in the same country as the organisation indicated during purchasing process;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for 2 to 5 people who work for the organisation indicated by the client during purchasing process, and who are in the same country as the organisation indicated during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
- - for the product preservation: saving the product in the memory of an unlimited number of computers belonging to the organisation indicated by the client during purchasing process; these computers must be located in the same country as the organisation indicated during purchasing process;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for an unlimited number of people who work for the organisation indicated by the client during purchasing process, who are in the same country as the organisation indicated during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
- - for the product preservation: saving the product in the memory of an unlimited number of computers belonging to the organisation indicated by the client during purchasing process; these computers can be located in or outside of the country of the organisation indicated during purchasing process;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for an unlimited number of people who work for the organisation indicated by the client during purchasing process, who are in or outside of the country of the organisation indicated during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.